No Data
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
guizhou sanli pharmaceutical co.,ltd. (603439.SH): plans to acquire 22.9111% equity of Hanfang Pharmaceutical
On December 3, Gelonhui reported that guizhou sanli pharmaceutical co.,ltd. (603439.SH) announced that the company intends to acquire Mr. Deng Daixing's 22.9111% equity stake in Guizhou Hanfang Pharmaceutical Co., Ltd. (referred to as "Hanfang Pharmaceutical"). The equity transfer price for this transfer is RMB 169.83 million, to be paid in cash. As of the date before this equity transfer, Hanfang Pharmaceutical was a controlling subsidiary of the company, with the company holding 75.8928% equity stake in it; after the completion of this equity transfer, the company will hold 98.8039% equity stake in Hanfang Pharmaceutical.
guizhou sanli pharmaceutical co.,ltd. (603439.SH): Among the products currently in production and for sale by guizhou sanli pharmaceutical co.,ltd., there are no products related to snakes.
Gelonghui November 26th | Guizhou Sanli Pharmaceuticals (603439.SH) stated on the interactive platform that currently Guizhou Sanli Pharmaceuticals does not have any products related to snakes among its production and sales. Subsidiaries Guizhou Hanfang Pharmaceutical, Guizhou Dechangxiang, and Yunnan Wudizhi Pharmaceuticals have products with snake-related raw materials in their formulations.
Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH) shareholder Guosheng Haitong Private Enterprise High-quality Development Fund completed the shareholding of 9900 shares, reducing the shareholding ratio to below 5%.
guizhou sanli pharmaceutical co.,ltd. (603439.SH) announced that the shareholder shanghai guosheng capital management co., ltd.-shanghai guoshenghaitong...
Is Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Latest Stock Performance A Reflection Of Its Financial Health?
guizhou sanli pharmaceutical co.,ltd. (603439.SH): Awarded 54 incentive targets 5.23 million restricted stocks.
Gelonghui November 8th | Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH) announced that the company's board of directors believes that the conditions for granting the restricted stocks incentive plan for the year 2024 have been met, and agreed to set November 8, 2024 as the grant date, granting 54 incentive objects 5.23 million restricted stocks.
Why Investors Shouldn't Be Surprised By Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) 30% Share Price Plunge
